{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:34:59Z","timestamp":1793727299998,"version":"4.6.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clim.2026.110766","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:28:26Z","timestamp":1787495306000},"page":"110766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis"],"prefix":"10.1016","volume":"288","author":[{"given":"Darin T.","family":"Okuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia M.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan C.","family":"Jones-McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy W.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal M.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Santoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter V.","family":"Sguigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"St\u00fcve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diem H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.","family":"Light","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatum M.","family":"Moog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom G.","family":"Punnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110766_bb0005","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","article-title":"Population-based estimates for the prevalence of multiple sclerosis in the United States by race, ethnicity, age, sex, and geographic region","volume":"80","author":"Hittle","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.clim.2026.110766_bb0010","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1212\/01.wnl.0000335764.14513.1a","article-title":"Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome","volume":"72","author":"Okuda","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2026.110766_bb0015","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1093\/brain\/awad073","article-title":"The radiologically isolated syndrome: revised diagnostic criteria","volume":"146","author":"Lebrun-Frenay","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.clim.2026.110766_bb0020","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.clim.2026.110766_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2025.2631","article-title":"Estimating costs of market exclusivity extensions for 4 top-selling prescription drugs in the US","volume":"6","author":"Hong","year":"2025","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.clim.2026.110766_bb0030","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1007\/s12325-026-03608-1","article-title":"Comparative effectiveness of Diroximel fumarate vs. dimethyl fumarate in persons with multiple sclerosis: a US claims analysis of relapse outcomes","volume":"43","author":"Bandari","year":"2026","journal-title":"Adv. Ther."},{"key":"10.1016\/j.clim.2026.110766_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104692","article-title":"The consequences of switching from Gilenya(R) to generics for fingolimod","volume":"74","author":"Menendez","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clim.2026.110766_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105760","article-title":"Underdosed generic specialty medications: a prescription for patient harm?","volume":"88","author":"Okuda","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.clim.2026.110766_bb0045","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241300047","article-title":"Clinical and radiological implications of subpotent generic fingolimod in multiple sclerosis: a case series","volume":"17","author":"Okuda","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clim.2026.110766_bb0050","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/13524585251401404","article-title":"Clinical and radiological outcomes of directed treatment transitions from Gilenya((R)) to generic fingolimod","volume":"32","author":"Patel","year":"2026","journal-title":"Mult. Scler."},{"key":"10.1016\/j.clim.2026.110766_bb0055","doi-asserted-by":"crossref","first-page":"D730","DOI":"10.1093\/nar\/gkae1113","article-title":"The STRING database in 2025: protein networks with directionality of regulation","volume":"53","author":"Szklarczyk","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.clim.2026.110766_bb0060","doi-asserted-by":"crossref","first-page":"28017","DOI":"10.1074\/jbc.M112.383380","article-title":"Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappaB (NF-kappaB) and extracellular signal-regulated kinase 1 and 2 (ERK1\/2) and mitogen stress-activated kinase 1 (MSK1) signaling","volume":"287","author":"Peng","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2026.110766_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120254","article-title":"Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro","volume":"10","author":"Brennan","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.clim.2026.110766_bb0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1124\/jpet.111.190132","article-title":"Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway","volume":"341","author":"Scannevin","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.clim.2026.110766_bb0075","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/sj.jid.5700686","article-title":"Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1","volume":"127","author":"Lehmann","year":"2007","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2026.110766_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9080700","article-title":"Exploring the use of dimethyl fumarate as microglia modulator for neurodegenerative diseases treatment","volume":"9","author":"Rosito","year":"2020","journal-title":"Antioxidants"},{"key":"10.1016\/j.clim.2026.110766_bb0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.clim.2026.110766_bb0090","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1038\/s41598-022-07024-7","article-title":"Teriflunomide shifts the astrocytic bioenergetic profile from oxidative metabolism to glycolysis and attenuates TNFalpha-induced inflammatory responses","volume":"12","author":"Kabiraj","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.clim.2026.110766_bb0095","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.clim.2026.110766_bb0100","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2025"},{"key":"10.1016\/j.clim.2026.110766_bb0105","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/(SICI)1097-0258(19960330)15:6<647::AID-SIM184>3.0.CO;2-P","article-title":"An asymptotic test for the equality of coefficients of variation from k populations","volume":"15","author":"Feltz","year":"1996","journal-title":"Stat. Med."},{"key":"10.1016\/j.clim.2026.110766_bb0110","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/13571516.2019.1654324","article-title":"Four facts concerning competition in U.S. generic prescription drug markets","volume":"27","author":"Conti","year":"2020","journal-title":"Int J. Econ. Bus."},{"key":"10.1016\/j.clim.2026.110766_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/prca.202200018","article-title":"Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis","volume":"17","author":"Qureshi","year":"2023","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.clim.2026.110766_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109688","article-title":"Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis","volume":"253","author":"Chitnis","year":"2023","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.clim.2026.110766_bb0125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1046\/j.1523-1747.2001.00211.x","article-title":"Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells","volume":"116","author":"Vandermeeren","year":"2001","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2026.110766_bb0130","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1074\/jbc.M204544200","article-title":"The transcriptional coactivator CREB-binding protein cooperates with STAT1 and NF-kappa B for synergistic transcriptional activation of the CXC ligand 9\/monokine induced by interferon-gamma gene","volume":"278","author":"Hiroi","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2026.110766_bb0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2011.01088.x","article-title":"The noncanonical NF-kappaB pathway","volume":"246","author":"Sun","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2026.110766_bb0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164189","article-title":"NF-kappaB-mediated CCL20 reigns dominantly in CXCR2-driven ovarian Cancer progression","volume":"11","author":"Ignacio","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.clim.2026.110766_bb0145","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-021-00799-9","article-title":"Pharmacokinetics and bioavailability of monomethyl fumarate following a single Oral dose of Bafiertam (monomethyl fumarate) or Tecfidera((R)) (dimethyl fumarate)","volume":"35","author":"Lategan","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clim.2026.110766_bb0150","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2125.2004.02145.x","article-title":"Pharmacokinetics of oral fumarates in healthy subjects","volume":"58","author":"Litjens","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.clim.2026.110766_bb0155","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejpb.2016.11.034","article-title":"Food, gastrointestinal pH, and models of oral drug absorption","volume":"112","author":"Abuhelwa","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.clim.2026.110766_bb0160","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.immuni.2012.11.012","article-title":"Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node","volume":"38","author":"Kastenmuller","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2026.110766_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2026.156586","article-title":"The dual role of CCL20 in inflammatory disease: maintenance of host defense and immunopathological balance","volume":"286","author":"Xu","year":"2026","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.clim.2026.110766_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/cells11172649","article-title":"The CXCL13\/CXCR5 immune Axis in health and disease-implications for intrathecal B cell activities in Neuroinflammation","volume":"11","author":"Harrer","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.clim.2026.110766_bb0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40263-020-00700-0","article-title":"Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: results from the randomized, double-blind, phase III EVOLVE-MS-2 study","volume":"34","author":"Naismith","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clim.2026.110766_bb0180","doi-asserted-by":"crossref","DOI":"10.1177\/1756286421993999","article-title":"Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study","volume":"14","author":"Wundes","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.clim.2026.110766_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111115","article-title":"Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study","volume":"9","author":"Claes","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.clim.2026.110766_bb0190","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jnen\/nly121","article-title":"Multiple sclerosis: destruction and regeneration of astrocytes in acute lesions","volume":"78","author":"Prineas","year":"2019","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.clim.2026.110766_bb0195","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1210\/jc.2008-2450","article-title":"Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in graves\u2019 disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"94","author":"Antonelli","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.clim.2026.110766_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/biom14121541","article-title":"CXCL13 as a biomarker: background and utility in multiple sclerosis","volume":"14","author":"Pachner","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.clim.2026.110766_bb0205","doi-asserted-by":"crossref","first-page":"5621","DOI":"10.4049\/jimmunol.168.11.5621","article-title":"Induction of macrophage-inflammatory protein-3alpha gene expression by TNF-dependent NF-kappaB activation","volume":"168","author":"Sugita","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2026.110766_bb0210","doi-asserted-by":"crossref","first-page":"63799","DOI":"10.18632\/oncotarget.19124","article-title":"Transmembrane TNF-alpha promotes activation-induced cell death by forward and reverse signaling","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clim.2026.110766_bb0215","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.26","article-title":"Synovial cell death is regulated by TNF-alpha-induced expression of B-cell activating factor through an ERK-dependent increase in hypoxia-inducible factor-1alpha","volume":"8","author":"Lee","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.clim.2026.110766_bb0220","first-page":"1114","article-title":"Large-scale plasma proteomic profiling unveils diagnostic biomarkers and pathways for Alzheimer's disease, Nat","volume":"5","author":"Heo","year":"2025","journal-title":"Aging"},{"key":"10.1016\/j.clim.2026.110766_bb0225","doi-asserted-by":"crossref","first-page":"4759","DOI":"10.1038\/s41467-024-48961-3","article-title":"Plasma proteomics identify biomarkers predicting Parkinson\u2019s disease up to 7 years before symptom onset","volume":"15","author":"Hallqvist","year":"2024","journal-title":"Nat. Commun."}],"updated-by":[{"DOI":"10.1016\/j.clim.2026.110778","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000}}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162600104X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162600104X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:59:25Z","timestamp":1793725165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152166162600104X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":45,"alternative-id":["S152166162600104X"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110766","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative multi-analyte serum protein differences between generic and brand-name dimethyl fumarate, fingolimod, and teriflunomide in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110766","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110766"}}